Device Trial Radar · NCT05507528
Evaluation of the Safety and Efficacy of REBORN System for Lipolysis Treatment
Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
107
Actual
Start
Jun 30, 2022
Primary completion
Nov 11, 2023
Study completion Nov 11, 2023
Sponsor
- Lead sponsor
- Lightfective LtdNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 19, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Lightfective ReBorn System is intended for non-invasive lipolysis of the flanks in individuals with a Body Mass Index (BMI) of 30 or less. The device is intended to affect the appearance of visible fat bulges in the flanks.
Conditions
- LIPOLYSIS
Interventions
reborn treatmentDevice
Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fat reductionTime frame: 20 weeks
- Blinded reviewers evaluationTime frame: 20 weeks
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Tennessee Clinical Research Center
Tennessee City, Tennessee
Herzelia Medical Center - Tal Nachliely clinic
Kiryat Bialik, Israel
rabin medical center - campus Hasharon
Petah Tikva, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.